Acrokeratosis Neoplastica Clinical Presentation

  • Author: Cary Chisholm, MD; Chief Editor: William D James, MD   more...
 
Updated: Mar 21, 2012
 

History

A diagnostic algorithm for acrokeratosis neoplastica has been proposed by Valdivielso, et al. At first suspicion of acrokeratosis paraneoplastica, a detailed history should be taken.[4]

The physician should inquire regarding risk factors for malignancy, including smoking habit, alcohol consumption, and family history. Upon further questioning, patients with suspected acrokeratosis neoplastica may admit to mild constitutional symptoms, weight loss, and other nonspecific findings of internal malignancy.

In one review of acrokeratosis neoplastica, when skin findings preceded the diagnosis of malignancy, they were present for an average of 1 year.[3] The interval between acrokeratosis paraneoplastica skin manifestations and tumor diagnosis has been reported to be as long as 3 years in some cases.[5] Signs of acrokeratosis paraneoplastica precede the detection of the primary malignancy in 65-70% of instances. Of acrokeratosis neoplastica patients, 10-15% have lesion appearance after the diagnosis of malignancy. In the remaining 15-25% of acrokeratosis neoplastica cases, both occur simultaneously.[6]

Next

Physical

A complete physical examination should be performed in all patients suspected of having acrokeratosis neoplastica. This should include a thorough head and neck examination, including endoscopic examination, and pelvic examination in women.[3, 4]

Cutaneous manifestations of acrokeratosis neoplastica are as follows:

  • Symmetrical, acral, scaly, red-to-violaceous plaques or patches
  • Involvement of the fingers, distal hands, feet, nose, and helices of the ears: Isolated involvement of the helices is particularly suggestive of acrokeratosis neoplastica.
  • Involvement of the cheeks, trunk, elbows, knees, palms, and soles in advanced disease
  • Nail dystrophy
  • Swelling of the digits with a blue-to-violet discoloration
  • Acrally distributed, hyperpigmented patches possible in persons with darker skin types
  • Bullae of the hands and feet

Three stages of lesion evolution have been described for acrokeratosis neoplastica. After performing the physical examination, the patient can be staged as follows[7] :

  • Stage 1: These acrokeratosis neoplastica patients have poorly defined psoriasiform plaques involving the ears, nose, nails, fingers, and toes. Nail folds become dystrophic at this stage.
  • Stage 2: These acrokeratosis neoplastica patients have involvement of larger and more proximal regions. Violaceous keratoderma with central clearing is seen over the cheeks, palms, and/or soles.
  • Stage 3: This acrokeratosis neoplastica stage is reached when lesions have spread over more distal sites such as the legs, knees, thighs, and arms.

Attention should also be paid to signs of other paraneoplastic syndromes, because patients may present with more than one.[8] Other physical examination findings suggesting the possibility of neoplasia are as follows:

Previous
Next

Causes

  • Most acrokeratosis neoplastica cases are associated with squamous cell carcinoma (SCC) of the upper one third of the respiratory or GI tracts (ie, oropharynx/larynx, lungs, esophagus).
  • Case reports also describe SCC of the thymus, vulva, and skin and of SCC with an unknown primary tumor.
  • Other reported associated tumors include poorly differentiated carcinoma (not otherwise specified), small cell carcinoma of the lung, lymphoma, ductal carcinoma of the breast, carcinoid, multiple myeloma, transitional cell carcinoma of the bladder, cholangiocarcinoma,[2] liposarcoma,[9] well-differentiated thymic carcinoma,[10] and adenocarcinoma of multiple primary sites including tonsils.[11]
Previous
 
 
Contributor Information and Disclosures
Author

Cary Chisholm, MD  Resident Physician, Department of Pathology, Texas A&M Health Science Center College of Medicine

Cary Chisholm, MD is a member of the following medical societies: College of American Pathologists, Texas Medical Association, and United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.

Coauthor(s)

Daniel D Bennett  MD, Assistant Professor

Daniel D Bennett is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Dermatology Foundation, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Jean-Hilaire Saurat, MD  Chair, Professor, Department of Dermatology, University of Geneva, Switzerland

Jean-Hilaire Saurat, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD  Assistant Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, and Texas Dermatological Society

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD  Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology

Disclosure: Elsevier Royalty Other

Additional Contributors

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Karen Allen, MD, to the development and writing of this article.

References
  1. Taher M, Grewal P, Gunn B, Tonkin K, Lauzon G. Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc. J Cutan Med Surg. Mar-Apr 2007;11(2):78-83. [Medline].

  2. Karabulut AA, Sahin S, Sahin M, Eksioglu M, Ustün H. Paraneoplastic acrokeratosis of Bazex (Bazex's syndrome): report of a female case associated with cholangiocarcinoma and review of the published work. J Dermatol. Dec 2006;33(12):850-4. [Medline].

  3. Taher M, Grewal P, Gunn B, Tonkin K, Lauzon G. Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc. J Cutan Med Surg. Mar-Apr 2007;11(2):78-83. [Medline].

  4. Valdivielso M, Longo I, Suarez R, Huerta M, Lazaro P. Acrokeratosis paraneoplastica: Bazex syndrome. J Eur Acad Dermatol Venereol. May 2005;19(3):340-4. [Medline].

  5. Crucitti A, Feliciani C, Grossi U, La Greca A, Porziella V, Giustacchini P. Paraneoplastic acrokeratosis (bazex syndrome) in lung cancer. J Clin Oncol. Dec 20 2009;27(36):e266-8. [Medline].

  6. Ljubenovic MS, Ljubenovic DB, Binic II, Jankovic AS, Jovanovic DL. Acrokeratosis paraneoplastica (Bazex syndrome). Indian J Dermatol Venereol Leprol. May-Jun 2009;75(3):329. [Medline].

  7. Chapireau D, Adlam D, Cameron M, et al. Paraneoplastic syndromes in patients with primary oral cancers: A systematic review. Br J Oral Maxillofacial Surg. 2009;epub ahead of print.

  8. da Rosa ACM, Pinto GM, Bortoluzzi JS, et al. Three simultaneous paraneoplastic manifestations (ichthyosis acquisita, Bazex syndrome, and Leser-Trelat sign) with prostate adenocarcinoma. J Am Acad Dermatol. 2009;61:538-540.

  9. Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma. J Am Acad Dermatol. Dec 2006;55(6):1103-5. [Medline].

  10. Chave TA, Bamford WM, Harman KE. Acrokeratosis paraneoplastica associated with recurrent metastatic thymic carcinoma. Clin Exp Dermatol. Jul 2004;29(4):430-2. [Medline].

  11. Ali M, Keir M, Dodd H, Cerio R. Flexural Bazex syndrome associated with tonsillar adenocarcinoma. J Drugs Dermatol. Sep-Oct 2004;3(5):557-9. [Medline].

  12. Cabanillas M, Perez-Perez L, Sanchez-Aguilar D, Fernandez-Redondo V, Toribio J. [Acrokeratosis paraneoplastica with bullous lesions associated with esophageal squamous cell carcinoma]. Actas Dermosifiliogr. Apr 2006;97(3):196-9. [Medline].

  13. Fasanmade A, Farrell K, Perkins CS. Bazex syndrome (acrokeratosis paraneoplastica): persistence of cutaneous lesions after successful treatment of an associated oropharyngeal neoplasm. Br J Oral Maxillofac Surg. Mar 2009;47(2):138-9. [Medline].

  14. Medenica L, Gajic-Veljic M, Škiljevic D, et al. Acrokeratosis paraneoplastica Bazex syndrome associated with eophageal squamocellular carcinoma. Vojnosanit Pregl. 2008;65:485-487.

Previous
Next
 
Acrokeratosis neoplastica. A 67-year-old woman presented with scaly plaques of the hands, feet, ears, and nose associated with esophageal squamous cell carcinoma. The eruption resolved with resection of the cancer. Image courtesy of Ronald Grimwood, MD.
Acrokeratosis neoplastica. A 67-year-old woman presented with scaly plaques of the hands, feet, ears, and nose associated with esophageal squamous cell carcinoma. The eruption resolved with resection of the cancer. Image courtesy of Ronald Grimwood, MD.
Bazex syndrome. Acquired palmar keratoderma in a woman with a history of breast cancer and recent primary lung cancer. Courtesy of Jeffrey J. Meffert, MD.
Bazex syndrome. Violaceous psoriasiform dermatitis on the ankles. Lung cancer appeared to be in remission; both keratoderma and psoriasiform plaques resolved quickly with clobetasol ointment. Courtesy of Jeffrey J. Meffert, MD.
At this power, a patchy lichenoid infiltrate of predominantly lymphocytes can be seen underneath an epidermis with psoriasiform hyperplasia and serum crust in the parakeratotic cornified layer (hematoxylin and eosin, 100X).
Focal vacuolar interface change is seen with associated pigment incontinence and exocytosis of lymphocytes (hematoxylin and eosin, 200X).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.